| 2.96 -0.035 (-1.17%) | 08-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.01 | 1-year : | 4.69 |
| Resists | First : | 3.44 | Second : | 4.01 |
| Pivot price | 2.98  |
|||
| Supports | First : | 2.35 | Second : | 1.69 |
| MAs | MA(5) : | 2.96  |
MA(20) : | 2.78 |
| MA(100) : | 1.77 |
MA(250) : | 1.91 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 68.2 |
D(3) : | 67.2 |
| RSI | RSI(14): 61 |
|||
| 52-week | High : | 3.71 | Low : | 0.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ STIM ] has closed above bottom band by 48.0%. Bollinger Bands are 52.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.04 - 3.06 | 3.06 - 3.08 |
| Low: | 2.89 - 2.9 | 2.9 - 2.92 |
| Close: | 2.93 - 2.96 | 2.96 - 2.99 |
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
Mon, 24 Aug 2026
Neuronetics (NASDAQ: STIM) backer spent about $20.7M of his own cash - Stock Titan
Wed, 19 Aug 2026
Neuronetics (NASDAQ: STIM) ex-officer lines up $464K stock sale - Stock Titan
Tue, 18 Aug 2026
Neuronetics (NASDAQ: STIM) holder plans $388K sale with part for taxes - Stock Titan
Fri, 14 Aug 2026
US$6.00 - That's What Analysts Think Neuronetics, Inc. (NASDAQ:STIM) Is Worth After These Results - simplywall.st
Tue, 11 Aug 2026
Neuronetics: Q2 Earnings Snapshot - kens5.com
Tue, 11 Aug 2026
Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 76 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 30.8 (%) |
| Held by Institutions | 54 (%) |
| Shares Short | 9,330 (K) |
| Shares Short P.Month | 7,680 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.23 |
| Profit Margin | -19.7 % |
| Operating Margin | -3.7 % |
| Return on Assets (ttm) | -10.6 % |
| Return on Equity (ttm) | -116.1 % |
| Qtrly Rev. Growth | 9.1 % |
| Gross Profit (p.s.) | 1 |
| Sales Per Share | 2.03 |
| EBITDA (p.s.) | -0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -6.89 |
| PEG Ratio | 0 |
| Price to Book value | 12.86 |
| Price to Sales | 1.45 |
| Price to Cash Flow | -21.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|